Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) just unveiled an announcement.
Thiogenesis Therapeutics Corp has announced plans to initiate a Phase 3 pivotal clinical trial for its lead compound, TTI-0102, aimed at treating nephropathic cystinosis. This next-generation cysteamine-based prodrug is designed to improve tolerability and simplify dosing, potentially offering once-daily oral administration. The trial will leverage insights from previous studies to refine dosing regimens, aiming to overcome limitations of existing therapies and improve patients’ quality of life.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company focused on developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases.
Average Trading Volume: 21,868
Technical Sentiment Signal: Sell
Current Market Cap: C$32.66M
Find detailed analytics on TTI stock on TipRanks’ Stock Analysis page.